|  | **Frequency** | | | **Overall survival\*** | |
| --- | --- | --- | --- | --- | --- |
| **Depth of**  **response** | Overall (N=173) | First-line IO/IO (n=90) | First-line TKI/IO (n=83) | No. of  events | 24-month survival  estimate (95% CI) |
| CR | 20 (12%) | 9 (10%) | 11 (13%) | 1 | 94% (65, 99) |
| PR1 | 21 (12%) | 9 (10%) | 12 (14%) | 1 | 100% |
| PR2 | 18 (10%) | 7 (8%) | 11 (13%) | 5 | 94% (63, 99) |
| PR3 | 29 (17%) | 9 (10%) | 20 (24%) | 8 | 79% (57, 91) |
| SD | 62 (36%) | 36 (40%) | 26 (31%) | 30 | 57% (42, 69) |
| PD | 22 (13%) | 19 (21%) | 3 (4%) | 12 | 52% (29, 71) |
| \*Median follow-up times for survivors is 32 months. | | | | | |